Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease(185 visite) Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, Garavaglia B, Brice A, Brunetti A, Bonavita V, De Michele G, Salvatore M, Pappata S, Barone P
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2004 Dec 14; 63(11): 2097-2103.
Tipo di articolo: Journal Article, Comparative Study, Research Support, N. I. H. , Extramural, Non-U. S. Gov'T, P. H. S.,
Impact factor: 5.973, Impact factor a 5 anni: 8.375
Parole chiave: 2beta Carbomethoxy 3beta (4 Iodophenyl)n (3 Fluoropropyl)nortropane, Dopamine Transporter, Iodine 123, Nortropane Derivative, Parkin, Unclassified Drug, Adult, Article, Clinical Article, Controlled Study, Disease Duration, Dopaminergic Activity, Female, Gene Mutation, Human, Motor Activity, Parkinson Disease, Priority Journal, Rating Scale, Single Photon Emission Computer Tomography, Adolescent, Age Of Onset, Corpus Striatum, Dna Mutational Analysis, Dopamine Plasma Membrane Transport Proteins, Genotype, Iodine Radioisotopes, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Parkinsonian Disorders, Radiopharmaceuticals, Sequence Deletion, Substantia Nigra, Emission-Computed, Single-Photon, Ubiquitin-Protein Ligases, 2beta Carbomethoxy 3beta (4 Iodophenyl) N (3 Fluoropropyl) Nortropane,
Affiliazioni:
*** IBB - CNR *** Biostructure and Bioimaging Inst., National Research Council, Napoli, Italy Department of Neurological Sciences, University Federico II, Napoli, Italy Dept. Biomorphological Funct. Sci., University Federico II, Napoli, Italy Dept. of Molecular Neurogenetics, C. Besta Neurological Institute, Milan, Italy INSERM U289, Dept. Genet., Cytogenet. Embriology, Pitie-Salpetriere Hosp., Paris, France
Riferimenti:
Schrag, A., Horris, A., Morley, D., Quinn, N., Jahanshahi, M., Young- versus older-onset Parkinson's disease: Impact of disease and psychosocial consequences (2003) Mov Disord, 18, pp. 1250-125
Kitada, T., Asakawa, S., Hattori, N., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism (1998) Nature, 392, pp. 605-608
Hattori, N., Kitada, T., Matsumine, H., Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals (1998) Ann Neurol, 44, pp. 935-941
Abbas, N., Lucking, C.B., Ricard, S., A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe (1999) Hum Mol Genet, 8, pp. 567-574
Lucking, C.B., Durr, A., Bonifati, V., Association between early-onset Parkinson's disease and mutations in the parkin gene (2000) N Engl J Med, 342, pp. 1560-1567
Periquet, M., Latouche, M., Lohmann, E., Parkin mutations are frequent in patients with isolated early-onset parkinsonism (2003) Brain, 126, pp. 1271-1278
Lohmann, E., Periquet, M., Bonifati, V., How much phenotypic variation can be attributed to parkin genotype? (2003) Ann Neurol, 54, pp. 176-185
Farrer, M., Chan, P., Chen, R., Lewy bodies and parkinsonism in families with parkin mutations (2001) Ann Neurol, 50, pp. 293-300
Mori, H., Kondo, T., Yokochi, M., Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q (1998) Neurology, 51, pp. 890-892
Hayashi, S., Wakabayashi, K., Ishikawa, A., An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene (2000) Mov Disord, 15, pp. 884-888
Broussolle, E., Lucking, C.B., Ginovart, N., Pollak, P., Remy, P., Durr, A., [18F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations (2000) Neurology, 55, pp. 877-879
Portman, A.T., Giladi, N., Leenders, K.L., The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations (2001) Neurology, 56, pp. 1759-1762
Hilker, R., Klein, C., Ghaemi, M., Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene (2001) Ann Neurol, 49, pp. 367-376
Khan, N.L., Brooks, D.J., Pavese, N., Progression of nigrostriatal dysfunction in a parkin kindred: An [ 18F]dopa PET and clinical study (2002) Brain, 125, pp. 2248-2256
Thobois, S., Ribeiro, M.J., Lohmann, E., Young-onset Parkinson disease with and without parkin gene mutations: A fluorodopa F 18 positron emission tomography study (2003) Arch Neurol, 60, pp. 713-718
Scherfler, C., Khan, N.L., Pavese, N., Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism (2004) Brain, 127, pp. 1332-1342
Gibb, W.R., Lees, A.J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease (1988) J Neurol Neurosurg Psychiatry, 51, pp. 745-752
Booji, J., Tissingh, G., Boer, G.J., [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease (1997) J Neurol Neurosurg Psychiatry, 62, pp. 133-140
Booij, J., Hemelaar, J.T.G.M., Speelman, J.D., De Bruin, K., Janssen, A.G.M., Van Royen, E.A., One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT (1999) J Nucl Med, 40, pp. 753-761
Varrone, A., Marek, K.L., Jennings, D., Innis, R.B., Seibyl, J.P., [123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy (2001) Mov Disord, 16, pp. 1023-1032
Goetz, C.G., Blasucci, L., Stebbins, G.T., Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? (1999) Neurology, 52, pp. 1227-1229
Oliveira, S.A., Scott, W.K., Martin, E.R., Parkin mutations and susceptibility alleles in late-onset Parkinson's disease (2003) Ann Neurol, 53, pp. 624-629
Shimura, H., Hattori, N., Kubo, S., Immunohistochemical and subcellular localization of Parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients (1999) Ann Neurol, 45, pp. 668-672
Shimura, H., Schlossmacher, M.G., Hattori, N., Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease (2001) Science, 293, pp. 263-269
Van Dyck, C.H., Seibyl, J.P., Malison, R.T., Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT (1995) J Nucl Med, 36, pp. 1175-1181
Lavalaye, J., Booij, J., Reneman, L., Habraken, J.B.A., Van Royen, E.A., Effect of age and gender on dopamine transporter imaging with [ 123I]FP-CIT SPET in healthy volunteers (2000) Eur J Nucl Med, 27, pp. 867-869
Mozley, P.D., Kim, H.J., Gur, R.C., Iodine-123-IPT SPECT imaging of CNS dopamine transporters: Nonlinear effects of normal aging on striatal uptake values (1996) J Nucl Med, 37, pp. 1965-1970
Lavalaye, J., Knol, R.J., De Bruin, K., Reneman, L., Janssen, A.G., Booij, J., [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication (2000) Eur J Nucl Med, 27, pp. 346-349
Dresel, S.H.J., Kung, M.P., Plössl, K., Meegalla, S.K., Kung, H.F., Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats (1998) Eur J Nucl Med, 25, pp. 31-39
Little, K.Y., Gorebig, J., Carroll, F.I., Mapili, J., Meador-Woodruff, J.H., Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites (1996) Brain Res, 742, pp. 313-316
Battaglia, G., Busceti, C.L., Cuomo, L., Continuous subcutaneous infusion of apomorphine rescues nigrostriatal dopaminergic terminals following MPTP injection in mice (2002) Neuropharmacology, 42, pp. 367-373
Ahlskog, J.E., Uitti, R.J., O'Connor, M.K., The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease (1999) Mov Disord, 14, pp. 940-946
Innis, R.B., Marek, K.L., Sheff, K., Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT (1999) Mov Disord, 14, pp. 436-442
Nurmi, E., Bergman, J., Eskola, O., Reproducibility and effect of levodopa on dopamine transporter function measurement: A [18F]CFT PET study (2000) J Cereb Blood Flow Metab, 20, pp. 1604-1609
Guttman, M., Stewart, D., Hussey, D., Wilson, A., Houle, S., Kish, S., Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD (2001) Neurology, 56, pp. 1559-1564
Booij, J., Busemann Sokole, E., Stabin, M.G., Janssen, A.G.M., De Bruin, K., Van Royen, E.A., Human biodistribution and dosimetry of [123I]FP-CIT: A potent radioligand for imaging of dopamine transporters (1998) Eur J Nucl Med, 25, pp. 24-30
Lucking, C. B., Durr, A., Bonifati, V., Association between early-onset Parkinson's disease and mutations in the parkin gene (2000) N Engl J Med, 342, pp. 1560-1567
Portman, A. T., Giladi, N., Leenders, K. L., The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations (2001) Neurology, 56, pp. 1759-1762
Khan, N. L., Brooks, D. J., Pavese, N., Progression of nigrostriatal dysfunction in a parkin kindred: An [18F] dopa PET and clinical study (2002) Brain, 125, pp. 2248-2256
Gibb, W. R., Lees, A. J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease (1988) J Neurol Neurosurg Psychiatry, 51, pp. 745-752
Goetz, C. G., Blasucci, L., Stebbins, G. T., Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? (1999) Neurology, 52, pp. 1227-1229
Oliveira, S. A., Scott, W. K., Martin, E. R., Parkin mutations and susceptibility alleles in late-onset Parkinson's disease (2003) Ann Neurol, 53, pp. 624-629
Van Dyck, C. H., Seibyl, J. P., Malison, R. T., Age-related decline in striatal dopamine transporter binding with iodine-123- -CIT SPECT (1995) J Nucl Med, 36, pp. 1175-1181
Mozley, P. D., Kim, H. J., Gur, R. C., Iodine-123-IPT SPECT imaging of CNS dopamine transporters: Nonlinear effects of normal aging on striatal uptake values (1996) J Nucl Med, 37, pp. 1965-1970
Dresel, S. H. J., Kung, M. P., Pl ssl, K., Meegalla, S. K., Kung, H. F., Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc] TRODAT-1 to the central dopamine transporters in rats (1998) Eur J Nucl Med, 25, pp. 31-39
Little, K. Y., Gorebig, J., Carroll, F. I., Mapili, J., Meador-Woodruff, J. H., Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites (1996) Brain Res, 742, pp. 313-316
Ahlskog, J. E., Uitti, R. J., O'Connor, M. K., The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease (1999) Mov Disord, 14, pp. 940-946
Innis, R. B., Marek, K. L., Sheff, K., Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I] -CIT (1999) Mov Disord, 14, pp. 436-442
Objective: To investigate whether the presence of parkin gene mutations is associated with different nigrostriatal impairment than other early-onset parkinsonism. Methods: Eighteen consecutive early-onset Parkinson disease (PD) patients (nine parkin and nine nonparkin patients) and six controls were studied with [123I]FP-CIT SPECT. Results: Parkin patients had longer disease duration (15 ± 9 vs 6 ± 2 years, p = 0.008) and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor score (35.8 ± 13.7 vs 22.8 ± 7.9, p = 0.025) than nonparkin patients. Caudate and putamen DAT density were reduced by 60% and 79% in parkin and by 43% and 70% in nonparkin patients. Multiple regression analysis showed that the UPDRS and the presence of parkin gene mutations, but not the disease duration, were significantly correlated with the striatal DAT density. Parkin patients showed a more symmetric DAT loss in both caudate and putamen as compared with nonparkin patients. Conclusions: Parkin-related disease may be associated with a higher degree of nigrostriatal impairment, independently of the clinical severity of the disease, and a more symmetric involvement as compared with non-parkin early-onset disease.
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(64 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(151 visite) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(204 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(139 visite) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 DettagliEsporta in BibTeXEsporta in EndNote
Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M * The EEE project(192 visite) Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980. Impact Factor:0 DettagliEsporta in BibTeXEsporta in EndNote
